Phase 2 N=37 Cabozantinib in Advanced Solid Malignancies
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=101 A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
Hematologic Cancer
Primary: Maximum Tolerated Dose (MTD) of Elotuzumab in Combination With Lenalidomide and Dexamethasone (Phase 1) — 20 mg/kg
Phase 2 N=22 Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Number of Subjects Progression-free at 12 Months Per RECIST 1.1 — 3 Participants
Phase 2 N=64 Cystic Fibrosis and Endothelial Function: At Rest and During Exercise
Cystic Fibrosis
Primary: Percentage Flow-Mediated Dilation (FMD) — 5.64; 5.32; 6.29; 7.21 percentage of change in FMD
Phase 2 N=55 Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Cervical Cancer
Primary: Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 16 participants
Phase 2 N=13 Modafinil for Smoked Cocaine Self-Administration
Cocaine Dependence
Primary: Cocaine Self-administration — 0; 0; 0; 2.2 Number of doses purchased
Phase 2 N=110 Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Acute Myeloid Leukemia
Primary: Incidence of Dose-Limiting Toxicity (DLT) to Determine Maximum Tolerated Dose in Schedule A and Schedule B of Dose Escalation Phase (Group 1 and Group 2) — 0; 0; 0; 0…
Phase 2 N=67 Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse, Large B-Cell, Lymphoma
Primary: Objective Response Rate (ORR) in Total Population Based on Investigator Assessment — 19.4; 25.0 Percentage of participants
Phase 2 N=224 Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Number of Participants Reporting Solicited Injection-Site Reactions Following Vaccination: Menactra® Vaccine (9 to 23 Months) — 15; 0; 15; 0 Participants
Phase 2 N=226 Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Lymphoma, Non-Hodgkin
Primary: Objective Response Rate (ORR) Based on Independent Review-Part A — 43.75; 27.08 percentage of participants — p=0.0001
Phase 2 N=510 Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
Macular Degeneration
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS)…
Phase 2 N=92 The Spot Sign for Predicting and Treating ICH Growth Study
Intracerebral Hemorrhage
Primary: Number of Study Subjects With Life-threatening Thromboembolic Complications — 1; 0; 0 Participants — p=1.00
Phase 2 N=42 Abiraterone Post Ketoconazole for Prostate Cancer
Prostate Cancer
Primary: Preliminary Evidence of Efficacy of Abiraterone Acetate — 20 Participants
Phase 2 N=194 Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Primary: Progression Free Survival (PFS) — 6.86; 13.00 weeks — p=0.0022
Phase 2 N=127 Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer
Ovarian Cancer
Primary: Colony Stimulating Factor (CSF-1) Expression in Ovarian Endosalpingiosis — 5; 130; 50 Modified H-Score — p=0.012